Abstract:Targeted therapy of antiangiogensis strategy is the standard treatment for metastatic renal cell cancer. In recent years, a number of new generation of antiangiogensis agents have been tested in clinical trials, some of which have achieved promising outcomes. Other pathway inhibitors such as inhibitors of mammalian target of rapamycin and fibroblast growth factor receptor pathway have made progresses in some extent.

Key words:Kidney neoplasms,Molecular targeted therapy,Vascular endothelial growth factor A